The Effect of α-GPC on Cognitive Function and Sports Performance

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age25-55
SponsorNanjing Nutrabuilding Bio-tech Co., Ltd.

About this trial

The goal of this clinical trial is to find out whether daily supplementation with Alpha-Glycerophosphocholine (α-GPC) can improve cognitive function and sports performance in healthy adults. It will also assess the safety and tolerability of α-GPC when taken over a 6-week period.

The main questions this study aims to answer are:

Does taking α-GPC every day improve cognitive performance on tests such as the Stroop Test, Go/No-go Test, Sustained Attention to Response Task (SART), and Digit-Symbol Substitution Test (DSST)? Does α-GPC enhance upper and lower body sports performance? Does α-GPC positively affect perceived mood, energy, and motivation? Is α-GPC safe and well tolerated compared to a placebo? Researchers will compare α-GPC (350 mg per day) to a placebo (an inactive substance that looks the same) in a randomized, double-blind study. Neither the participants nor the researchers will know who receives α-GPC or the placebo.

Participants will:

Be randomly assigned to take either α-GPC or placebo capsules once daily for 6 weeks Attend 3 study visits over an 8-week period at Atlantia Clinical Trials in Cork, Ireland Complete cognitive and physical performance tests both acutely (shortly after a single dose) and after 6 weeks of daily use Have their vital signs, body weight, and any adverse events monitored throughout the study Record their diet and well-being during the study period This study will include 80 healthy adults aged 25-55 years who regularly engage in physical activity. The results will help determine whether α-GPC has benefits for brain function and physical performance, and whether it is safe for long-term use.

Eligibility criteria

Qualifiers

Be able to give written informed consent.

Be in good health as determined by the investigator.

Age between 25 and 55 years (inclusive).

Body Mass Index of 18.5-32.0 kg/m2 (inclusive).

Disqualifiers

Highly trained or competitive athletes.

Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.

Female participants who are currently breastfeeding.

Female participants who are planning to become pregnant during the study period.

Trial design

Treatments tested in this trial

  • Alpha-Glycerophosphocholine(α-GPC)
  • Microcrystalline Cellulose (placebo)

Treatment groups

80 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Nanjing Nutrabuilding Bio-tech Co., Ltd.

Lead sponsor

Atlantia Food Clinical Trials

Collaborator